Pharmacogenetics of Oral Antidiabetic Drugs
Oral antidiabetic drugs (OADs) are used for more than a half-century in the treatment of type 2 diabetes. Only in the last five years, intensive research has been conducted in the pharmacogenetics of these drugs based mainly on the retrospective register studies, but only a handful of associations d...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Hindawi Publishing Corporation
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845331/ |
| id |
pubmed-3845331 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-38453312013-12-09 Pharmacogenetics of Oral Antidiabetic Drugs Becker, Matthijs L. Pearson, Ewan R. Tkáč, Ivan Review Article Oral antidiabetic drugs (OADs) are used for more than a half-century in the treatment of type 2 diabetes. Only in the last five years, intensive research has been conducted in the pharmacogenetics of these drugs based mainly on the retrospective register studies, but only a handful of associations detected in these studies were replicated. The gene variants in CYP2C9, ABCC8/KCNJ11, and TCF7L2 were associated with the effect of sulfonylureas. CYP2C9 encodes sulfonylurea metabolizing cytochrome P450 isoenzyme 2C9, ABCC8 and KCNJ11 genes encode proteins constituting ATP-sensitive K+ channel which is a therapeutic target for sulfonylureas, and TCF7L2 is a gene with the strongest association with type 2 diabetes. SLC22A1, SLC47A1, and ATM gene variants were repeatedly associated with the response to metformin. SLC22A1 and SLC47A1 encode metformin transporters OCT1 and MATE1, respectively. The function of a gene variant near ATM gene identified by a genome-wide association study is not elucidated so far. The first variant associated with the response to gliptins is a polymorphism in the proximity of CTRB1/2 gene which encodes chymotrypsinogen. Establishment of diabetes pharmacogenetics consortia and reduction in costs of genomics might lead to some significant clinical breakthroughs in this field in a near future. Hindawi Publishing Corporation 2013 2013-11-13 /pmc/articles/PMC3845331/ /pubmed/24324494 http://dx.doi.org/10.1155/2013/686315 Text en Copyright © 2013 Matthijs L. Becker et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Becker, Matthijs L. Pearson, Ewan R. Tkáč, Ivan |
| spellingShingle |
Becker, Matthijs L. Pearson, Ewan R. Tkáč, Ivan Pharmacogenetics of Oral Antidiabetic Drugs |
| author_facet |
Becker, Matthijs L. Pearson, Ewan R. Tkáč, Ivan |
| author_sort |
Becker, Matthijs L. |
| title |
Pharmacogenetics of Oral Antidiabetic Drugs |
| title_short |
Pharmacogenetics of Oral Antidiabetic Drugs |
| title_full |
Pharmacogenetics of Oral Antidiabetic Drugs |
| title_fullStr |
Pharmacogenetics of Oral Antidiabetic Drugs |
| title_full_unstemmed |
Pharmacogenetics of Oral Antidiabetic Drugs |
| title_sort |
pharmacogenetics of oral antidiabetic drugs |
| description |
Oral antidiabetic drugs (OADs) are used for more than a half-century in the treatment of type 2 diabetes. Only in the last five years, intensive research has been conducted in the pharmacogenetics of these drugs based mainly on the retrospective register studies, but only a handful of associations detected in these studies were replicated. The gene variants in CYP2C9, ABCC8/KCNJ11, and TCF7L2 were associated with the effect of sulfonylureas. CYP2C9 encodes sulfonylurea metabolizing cytochrome P450 isoenzyme 2C9, ABCC8 and KCNJ11 genes encode proteins constituting ATP-sensitive K+ channel which is a therapeutic target for sulfonylureas, and TCF7L2 is a gene with the strongest association with type 2 diabetes. SLC22A1, SLC47A1, and ATM gene variants were repeatedly associated with the response to metformin. SLC22A1 and SLC47A1 encode metformin transporters OCT1 and MATE1, respectively. The function of a gene variant near ATM gene identified by a genome-wide association study is not elucidated so far. The first variant associated with the response to gliptins is a polymorphism in the proximity of CTRB1/2 gene which encodes chymotrypsinogen. Establishment of diabetes pharmacogenetics consortia and reduction in costs of genomics might lead to some significant clinical breakthroughs in this field in a near future. |
| publisher |
Hindawi Publishing Corporation |
| publishDate |
2013 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845331/ |
| _version_ |
1612032251937161216 |